Singapore Paincare Holdings Limited: Extension of Trading Halt – Key Details for Investors

Summary of Key Points

• Trading Halt Extension: Singapore Paincare Holdings Limited (“the Company”) has announced an extension of its trading halt, which was initially requested at 7:41 a.m. on 26 November 2025.
• Regulatory Compliance: Under Catalist Rule 1302(4), trading halts cannot exceed three market days unless the Singapore Exchange Securities Trading Limited (SGX-ST) agrees to a short extension.
• Reason for Extension: The Company requires additional time to prepare an update for shareholders regarding the Scheme previously announced on 28 May 2025.
• SGX-ST Approval: After discussions with SGX-ST, the Company, through its Continuing Sponsor, has secured an additional three market days for the trading halt. Trading will resume no later than 8:30 a.m. on Thursday, 4 December 2025.
• Leadership Communication: The update is formally communicated by Mr. Lee Mun Kam Bernard, Executive Chairman and Chief Executive Officer, on behalf of the Board.

Important Information for Shareholders

• Potential Price Sensitivity: The ongoing trading halt and its extension are significant events. Trading halts usually signal pending material announcements that could affect the share price once the halt is lifted.
• Pending Scheme Update: The Company has indicated that the trading halt is directly related to a forthcoming update about the Scheme mentioned in their 28 May 2025 announcement. The nature of this Scheme has not been disclosed in this announcement, but its importance is underscored by the need for extended halt and regulatory consultation.
• Market Uncertainty: The lack of immediate disclosure regarding the Scheme’s details introduces short-term uncertainty for shareholders, which can be price sensitive, especially once the contents of the update are released.
• Regulatory Oversight: The extension was granted after consultation with the exchange, indicating the matter’s seriousness and the importance of regulatory compliance.
• Communication Channel: Shareholders with questions can contact the Company’s sponsor, Novus Corporate Finance Pte. Ltd., specifically Mr. Pong Chen Yih, Chief Operating Officer.

Implications for Share Value

The fact that Singapore Paincare Holdings Limited has requested and received an extension to the trading halt signals that a material development is imminent. Such halts are often associated with events that could significantly impact the Company’s valuation—potentially positive or negative—once more information is made available to the market. Shareholders should closely monitor upcoming disclosures, especially regarding the Scheme, as these are likely to be price sensitive.

Next Steps for Investors

• Remain alert for the Company’s upcoming update, which is expected to be released before the trading halt is lifted by 8:30 a.m. on 4 December 2025.
• Consider the potential for increased share price volatility upon the resumption of trading, as the market digests the new information.
• Reach out to the Company’s sponsor for any urgent inquiries or clarifications during the trading halt period.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The contents are based on the Company’s official announcements. Investors should exercise caution and consult their own financial advisors before making investment decisions. The Singapore Exchange Securities Trading Limited assumes no responsibility for the accuracy or completeness of this communication.

View Sing Paincare Historical chart here